Shionogi & Co., Ltd.
Stock Price Chart
2026/07/10 UpdatedPrice Trend
2026/07/10 UpdatedPrice & Trading Details
2026/07/10 UpdatedPRICE
TRADING
Analyst Recommendations 11 analysts
Updated 2026/07/01Earnings Calendar
Updated 2026/07/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/01/29 | ¥68.45 | ¥87.76 | +28.2% |
| 2025/10/27 | ¥50.55 | ¥51.93 | +2.7% |
| 2025/07/28 | ¥42.54 | ¥46.26 | +8.7% |
| 2025/05/12 | ¥43.20 | ¥43.06 | -0.3% |
Shareholder Composition
Updated 2026/07/01Top Mutual Funds / ETFs
Updated 2026/07/01Major Holders
Updated 2026/07/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund
|
20.4M | +9.65% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
11.0M | +0.84% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
7.3M | +2.14% | |
|
HARDING LOEVNER Fd.S INC-Harding Loevner Intl Eqy. PORT.
|
6.2M | -3.79% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
5.4M | +0.59% | |
|
John Hancock Funds III-International Growth Fund
|
3.2M | 0.00% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
465.1K | +6.79% |
Dividend History
Updated 2026/07/05| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥38 | -42.4% |
| 2025 | ¥66 | +16.5% |
| 2024 | ¥57 | +13.3% |
| 2023 | ¥50 | +25.0% |
| 2022 | ¥40 | - |
Financial Performance
2026/07/05 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥335,138M | ¥426,684M | ¥435,081M | ¥438,268M |
| Gross Profit | ¥279,722M | ¥364,437M | ¥377,479M | ¥374,441M |
| Operating Income | ¥110,312M | ¥149,004M | ¥153,312M | ¥156,604M |
| Pretax Income | ¥127,109M | ¥224,832M | ¥204,984M | ¥209,777M |
| Net Income | ¥114,185M | ¥184,965M | ¥162,030M | ¥170,435M |
| EPS | ¥126.21 | ¥207.03 | ¥186.11 | - |
| Operating Margin | 32.92% | 34.92% | 35.24% | 35.73% |
| Balance Sheet | ||||
| Total Assets | ¥1,150,601M | ¥1,311,800M | ¥1,416,918M | ¥1,535,349M |
| Total Equity | ¥975,661M | ¥1,100,046M | ¥1,235,325M | ¥1,361,924M |
| Total Liabilities | ¥174,940M | ¥211,754M | ¥181,593M | ¥173,425M |
| Cash | ¥254,420M | ¥309,224M | ¥358,090M | ¥374,795M |
| Interest-bearing Debt | ¥6,674M | ¥9,411M | ¥11,620M | ¥21,882M |
| Equity Ratio | 84.80% | 83.86% | 87.18% | 88.70% |
| D/E Ratio | 0.01 | 0.01 | 0.01 | 0.02 |
| Cash Flow | ||||
| Operating CF | ¥102,068M | ¥177,867M | ¥154,284M | ¥195,460M |
| Investing CF | -¥96,204M | -¥48,292M | ¥5,922M | -¥116,080M |
| Financing CF | -¥36,615M | -¥84,123M | -¥126,853M | -¥64,908M |
| Free CF | ¥70,504M | ¥140,680M | ¥126,017M | ¥143,357M |
| Efficiency | ||||
| ROE | 11.70% | 16.81% | 13.12% | 12.51% |
| ROA | 9.92% | 14.10% | 11.44% | 11.10% |
Latest IR Information
-
Initiatives Toward Realizing Management that Considers Capital Cost and Stock Price
Shionogi & Co., Ltd. is promoting the enhancement of management functions, operational efficiency, and corporate strategies aimed at realizing management that takes into account capital costs and stock prices. The company aims to maximize corporate value through proactive IR activities...
Read more -
[Shionogi & Co., Ltd.] Additional Approval for Pediatric Use of COVID-19 Treatment | June 2026
Shionogi & Co., Ltd. has obtained approval for an expanded pediatric dose and administration method of the anti-SARS-CoV-2 drug Zocova, extending its application to children aged 6 to under 12 years old weighing at least 20kg. Safety and blood concentration...
Read more -
【Shionogi & Co., Ltd.】Favorable Results in Clinical Trial of New Antifungal Orolofym｜June 2026
Shionogi & Co., Ltd. announced that the Phase 3 global clinical trial of the novel antifungal Orolofym achieved the primary endpoint and demonstrated good safety profile. Approval applications are planned in Europe and Asia going forward.
Read more -
FDA Approval for New COVID-19 Treatment | Shionogi & Co., Ltd. May 2026
Shionogi & Co., Ltd. obtained FDA approval in the United States for the anti-SARS-CoV-2 drug ensitrelvir on June 16, 2026. This achievement marks the first oral antiviral medication approved for post-exposure prophylaxis of COVID-19 globally, representing a significant advancement that...
Read more -
[Shionogi & Co., Ltd.] Nardemizin New Drug Approved in China | May 2026
Shionogi & Co., Ltd. received approval for a new drug, Nardemizin, in China, contributing to the treatment of opioid-induced constipation. The approval was granted on May 27, 2026, and further market penetration and business expansion are anticipated.
Read more
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥3,388
Rating Score: 2.33 (Based on 11 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. It is also involved in consumer healthcare business; manufacturing, sale, analytical testing, and pharmaceutical engineering of medicinal drugs and investigational drugs; contracted monitoring of epidemiological components in sewage; promotion of implementation in social infrastructure; and business related to providing data and information; develops and sells foothold; and research and development of mucosal vaccines. In addition, the company provides contract support services for experimental research; contract testing of agricultural production materials; solutions for education and healthcare, system development, human resource development, and training business; marketing support services; and IT services for medical and healthcare-related issues. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. The company was founded in 1878 and is headquartered in Kita, Japan.
